Lonza, which a decade ago bought a Belgian plant to increase its peptide capacity, is selling the operation to peptide manufacturing specialist PolyPeptide…

With approval from local officials in Ireland now in hand, Shire says work on a $400 million biologics plant can begin.

Sanofi is jumping into the Rituxan biosimilars fray in a potential $200 million-plus deal with JHL Biotech, putting the Taiwan-based drugmaker's new China…

Japan’s Takeda, which expects its new multiple myeloma drug to be a big performer, is expanding API production for it with a new plant in Ireland. 

Sandoz and the FDA struck a deal earlier this year to let the generic unit of Novartis import from a Canadian plant an infant parenteral nutrition product…

The FDA has issued a warning letter to a Chinese heparin maker for some of the same kinds of issues raised by the EU earlier this year.

Japan’s Takeda is making a big push with a vaccine for dengue and says to be prepared it will build a €100 million plant at its manufacturing site in Singen,…

Leerink analysts think problems cited by the FDA for a Sanofi plant in France could spell issues for not one but two potential blockbusters under FDA review.

Manufacturing